Expense ManagementR&D and SG&A expenses came in lower than prior estimates, indicating better cost management.
Financial PositionKronos ended with $136.6M in cash, cash equivalents, and marketable securities, providing an operational runway.
Strategic AlternativesKronos is exploring strategic alternatives, including potential transactions involving its two proprietary p300 KAT inhibitors under preclinical development, which could unlock significant value for stakeholders.